Spyre Therapeutics, Inc.
SYRE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $886 | $2,329 | $18,739 |
| % Growth | -100% | -62% | -87.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $886 | $2,329 | $18,739 |
| % Margin | – | 100% | 100% | 100% |
| R&D Expenses | $162,790 | $89,504 | $58,579 | $57,069 |
| G&A Expenses | $45,776 | $39,946 | $28,531 | $27,319 |
| SG&A Expenses | $45,776 | $39,946 | $28,531 | $27,319 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $113,739 | $0 | $0 |
| Operating Expenses | $208,566 | $243,189 | $87,110 | $84,388 |
| Operating Income | -$208,566 | -$242,303 | -$84,781 | -$65,649 |
| % Margin | – | -27,348% | -3,640.2% | -350.3% |
| Other Income/Exp. Net | $599 | -$96,513 | $830 | -$11 |
| Pre-Tax Income | -$207,967 | -$338,816 | -$83,951 | -$65,660 |
| Tax Expense | $51 | -$26 | -$136 | $141 |
| Net Income | -$208,018 | -$338,790 | -$83,815 | -$65,801 |
| % Margin | – | -38,238.1% | -3,598.8% | -351.1% |
| EPS | -3.18 | -46.15 | -24.86 | -25.02 |
| % Growth | 93.1% | -85.6% | 0.6% | – |
| EPS Diluted | -3.18 | -46.15 | -24.86 | -25.02 |
| Weighted Avg Shares Out | 47,028 | 6,897 | 3,371 | 2,630 |
| Weighted Avg Shares Out Dil | 47,028 | 6,897 | 3,371 | 2,630 |
| Supplemental Information | – | – | – | – |
| Interest Income | $21,312 | $6,147 | $837 | $111 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $964 | $1,964 | $1,576 |
| EBITDA | -$207,967 | -$127,600 | -$82,817 | -$64,073 |
| % Margin | – | -14,401.8% | -3,555.9% | -341.9% |